1 / 7

ADDITION-Cambridge

ADDITION-Cambridge. Objective Assess the impact of a population-based screening program on mortality among people at high risk of undiagnosed diabetes. ADDITION-Cambridge. Study Design Cluster-randomized, controlled trial

francis-horton
Télécharger la présentation

ADDITION-Cambridge

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ADDITION-Cambridge Objective • Assess the impact of a population-based screening program on mortality among people at high risk of undiagnosed diabetes

  2. ADDITION-Cambridge Study Design • Cluster-randomized, controlled trial • Study population: 20,184 individuals (mean age 58 years, 64% men) from 32 general practices, who were considered to be at high risk of diabetes based on a validated risk score • 27 practices were randomly assigned to a screening group (n=16,047) and 5 practices to a no-screening control group (n=4137) • Patients and practitioners in the no-screening group were unaware of the patients’ high-risk status • All participants were tagged for mortality at the Office for National Statistics and followed for 10 years

  3. ADDITION-Cambridge Primary Analysis • Comparison of all-cause mortality rates and CV, cancer, and diabetes-related mortality rates between the screening and control groups Findings • Over a median follow-up of 9.6 years, 15,089 (94%) of the high-risk individuals in screening practices were invited for screening • 11,737 (73.1%) attended • 466 (2.9%) were diagnosed with diabetes • 4137 subjects were followed in the no-screening practices • There were no differences in mortality rates by study group

  4. ADDITION-Cambridge Cumulative Incidence Rate

  5. ADDITION-Cambridge Mortality Rate by Study Group

  6. ADDITION-Cambridge Conclusion • The benefits of screening for diabetes may have been overestimated and limited to those who are diagnosed and treated early • The benefits of screening might be improved by • The detection and management of related CV risk factors alongside assessment of diabetes risk • Repeated rounds of screening • The identification of non-attenders and strategies to maximize their utilization of screening

More Related